Status:
COMPLETED
Safety and Effectiveness Study of the Reflection Ceramic Acetabular System
Lead Sponsor:
Smith & Nephew, Inc.
Conditions:
Osteoarthritis
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
This Post-Approval study is prospective follow-up study designed to evaluate the long-term safety and effectiveness of the Reflection Ceramic Acetabular System.
Detailed Description
This Post-Approval study is prospective follow-up study designed to evaluate the long-term safety and effectiveness of the Reflection Ceramic Acetabular System. Randomized Non-inflammatory Arthritis, ...
Eligibility Criteria
Inclusion
- Criteria
- (Patient must meet all of the following characteristics to be enrolled in the study):
- Males and females, 21 to 80 years of age, inclusive;
- Primary diagnosis of non-inflammatory arthritis (osteoarthritis) or inflammatory arthritis (rheumatoid arthritis), or patients requiring a revision as specified previously;
- The patient or his/her legal guardian is willing to consent to participate in the study by signing and dating the approved consent form;
- The patient will be available for follow-up through at least two years postoperative;
- The patient has met an acceptable preoperative medical clearance and is free or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk (FDA requirement);
- The patient has a total Harris Hip Score of less than or equal to 60 (FDA requirement);
- The patient meets none of the exclusion criteria.
Exclusion
- (Patient with any of the following characteristics must be excluded from the study):
- Patients known to have insufficient quantity or quality of bone support resulting from Conditions such as cancer, femoral osteotomy, Girdlestone resection, significant osteoporosis or metabolic disorders of calcified tissues. Patients with physical conditions tending to place extreme loads on implants such as morbid obesity (\> 100 pounds over desirable body weight), Charcot joints, muscle deficiencies, or multiple joint disabilities;
- Patients with active localized or systemic infection;
- Patients who have not reached full skeletal maturity;
- Patient psychological or neurological conditions which tend to preempt the patient's ability or willingness to restrict activities or follow medical advice, especially during the postoperative period, e.g.: drug or alcohol abuse, serious mental illness or retardation, or general neurological conditions;
- The patient is participating in any other pharmaceutical, biologic or medical device clinical investigation;
- Immunosuppressive disorders - immunosuppressive disorders are chronic conditions characterized by markedly inhibited ability to respond to antigenic stimuli. Examples of such conditions include patients who are on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses), patients receiving therapy to prevent homograft rejection, patients who have acquired immunodeficiency syndrome (AIDS), or auto-immune diseases (except rheumatoid arthritis).
- Pregnancy.
- Patients with known sensitivity to materials in the device.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT00663351
Start Date
December 1 2004
End Date
December 1 2014
Last Update
October 13 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Georgia, Department of Orthopaedics
Augusta, Georgia, United States, 30912
2
Family Orthopaedics
Flint, Michigan, United States, 48507
3
Hospital of Joint Disease, Orthopaedic Institute
New York, New York, United States, 10003
4
Presbyterian Medical Center, Department of Orthopaedic Surgery
Philadelphia, Pennsylvania, United States, 19104-2699